Incidence, Management, and Outcomes of Eyes with Comorbid Active Uveitis and Central Serous Chorioretinopathy
- PMID: 40184582
- DOI: 10.1097/IAE.0000000000004478
Incidence, Management, and Outcomes of Eyes with Comorbid Active Uveitis and Central Serous Chorioretinopathy
Abstract
Purpose: To investigate the incidence, management, and outcomes of eyes with active uveitis and central serous chorioretinopathy (CSCR).
Methods: Retrospective chart review.
Results: Of 4,034 patients diagnosed with uveitis during the 8-year study period, 20 (0.5%) had comorbid active uveitis and CSCR, followed for a median of 34 months. Patients were stratified based on diagnoses sequence. In Cohort 1, 4 eyes (3 patients) initially diagnosed with active uveitis and later developed active CSCR at a median of 65 days following corticosteroid initiation, with resolution of CSCR occurring in all eyes at a median of 104 days after withdrawing corticosteroids. Three eyes (2 patients) developed worsening inflammation upon corticosteroid withdrawal requiring corticosteroid-sparing immunosuppression. In Cohort 2, 21 eyes (17 patients) with inactive CSCR were later diagnosed with active uveitis. Fifteen eyes (12 patients) were treated with corticosteroids and 9 eyes (8 patients) developed active CSCR. The CSCR persisted after corticosteroid withdrawal in 6 eyes (5 patients) necessitating targeted therapy for CSCR. The other 6 eyes (5 patients) of Cohort 2 were observed or treated with topical NSAIDS with resolution of uveitis. All patients had inactive uveitis and CSCR at final follow-up.
Conclusions: A complex relationship exists between CSCR and uveitis. Control of both diseases is possible through judicious use of corticosteroids, non-steroidal immunosuppression, and therapies targeted at persistent CSCR.
Keywords: Central Serous Chorioretinopathy; Corticosteroids; Intraocular Inflammation; Uveitis.
Similar articles
-
Central serous chorioretinopathy, corticosteroids, and uveitis.Ocul Immunol Inflamm. 2012 Apr;20(2):76-85. doi: 10.3109/09273948.2011.650776. Ocul Immunol Inflamm. 2012. PMID: 22409559 Review.
-
Central Serous Chorioretinopathy Misdiagnosed as Posterior Uveitis and the Vicious Circle of Corticosteroid Therapy.J Ophthalmic Vis Res. 2015 Jul-Sep;10(3):303-8. doi: 10.4103/2008-322X.170352. J Ophthalmic Vis Res. 2015. PMID: 26730317 Free PMC article.
-
One year outcome and predictors of treatment outcome in central serous chorioretinopathy: Multimodal imaging based analysis.Eur J Ophthalmol. 2022 Jul;32(4):2319-2327. doi: 10.1177/11206721211055018. Epub 2021 Nov 6. Eur J Ophthalmol. 2022. PMID: 34747194
-
Half-fluence Photodynamic Therapy for Central Serous Chorioretinopathy in a Patient Receiving Corticosteroids for Behçet's Uveitis.Turk J Ophthalmol. 2022 Apr 28;52(2):142-146. doi: 10.4274/tjo.galenos.2022.96461. Turk J Ophthalmol. 2022. PMID: 35481736 Free PMC article.
-
Current Choroidal Imaging Findings in Central Serous Chorioretinopathy.Vision (Basel). 2020 Oct 16;4(4):44. doi: 10.3390/vision4040044. Vision (Basel). 2020. PMID: 33081096 Free PMC article. Review.
LinkOut - more resources
Full Text Sources